REVIEWUnmet needs in paediatric psychopharmacology: Present scenario and future perspectives
Introduction
All theoretical frameworks to describe and analyse psychological functioning and human behaviour invariably view childhood and adolescence as crucial to the development of life-long mental health and disease. In recent decades, the growth of basic neuroscience has indeed pushed developmental psychology beyond limited descriptions and interpretations of human cognitive, emotional and behavioural trajectories, into a bio-psycho-social framework where the neurobiological underpinnings of typical development hold a key position (Lee et al., 2014, Schumann et al., 2014). Within this framework, the link between abnormal neurodevelopment and paediatric psychopathology has become the object of intense investigation, which holds a realistic promise to produce major advances in developmental neuropsychopharmacology in the not-so-distant future. Furthermore, adult psychiatric disorders have been shown to at least partly stem from neurodevelopmental abnormalities arising from early or late childhood, if not even prenatally (Salum et al., 2010).
Recognizing this great potential for major upcoming progress in clinical practice, but also acknowledging the serious limitations of current psychopharmacological interventions in paediatric neuropsychiatry, the Child & Adolescent Neuropsychopharmacology Network of the European College of Neuropsychopharmacology (ECNP; http://www.ecnp.eu/) held a Targeted Network Meeting (TNM) on October 4, 2013, satellite to the 26th Annual ECNP Congress (Barcelona, Spain). Thirteen experts presented evidence, shared opinions, described policies and debated views around the many unmet needs in child psychopharmacology. In the ensuing year, a dialogue on these subjects was continued by the participants with the goal of producing the present meeting report, which provides a snapshot of the most critical unmet needs, summarized in Table 1, as well as a general framework to guide future collaborative efforts and advance the field of paediatric psychopharmacology.
Section snippets
The off-label prescription to children and adolescents of medications with regulatory approval only in adults
Developmental neuropsychopharmacology has progressively evolved from considering youth as “small adults”, to investigating new fields of interest specific to children and adolescents (Arango, 2015). However, to date only very few medications have been approved in Europe for use in children and adolescents (Table 2). Many psychotropic medications prescribed to paediatric patients are unlicensed and off-label. In fact, the vast majority of medicines prescribed to children throughout the European
The lack of effective drugs for many childhood disorders
No curative and only few symptomatically effective pharmacological agents are currently available for the treatment of psychiatric disorders with onset in childhood and adolescence. Disorders with the largest unmet needs were identified and prioritized by experts attending the TNM meeting as displayed in Fig. 1, underscoring the critical importance of finding effective drug treatments especially for autism spectrum disorder, bipolar disorder, anorexia nervosa and other eating disorders, conduct
In search for evidence-based approaches to prevent psychiatric disorders with adolescent-onset
Adolescence is a period of extraordinary physical, psychological and social growth: personal and gender identity, morals and ideals, relationships with peers and adults, all undergo major reshaping to finalize their developmental trajectory and form a fully “adult” self. Major hormonal and neurobiological changes underlie these phenomena: following overproduction of synapses during childhood, adolescence fosters the selection and stabilization of relevant synaptic contacts, paralleled by
The need for better preclinical data to foster novel drug therapies
The importance of preclinical data in setting the stage for appropriately targeted and well-designed clinical trials has clearly emerged in previous sections. Here, we shall focus on four specific approaches, namely genetics, animal models, induced pluripotent stem cells (iPSC), and non-coding RNAs. Each represents a promising preclinical avenue for the advancement of child psychopharmacology, but each also presents with limitations and caveats.
- (A)
Human genetics represents one major foundation
Paediatric clinical trials: Methodological issues, problems and potential solutions
Randomized clinical trials (RCTs) have contributed remarkably to paediatric psychopharmacology. We can now legitimately talk of evidence-based psychopharmacology for children and adolescents because dozens of RCTs have investigated the benefits and tolerability/safety of various psychotropic medications during development. While the epistemological value of RCTs in paediatric psychopharmacology is undeniable, two main types of concerns have emerged over this experimental design:
- (a)
The external
The regulatory context of paediatric psychopharmacology in Europe: Strengths and limitations
To address the need for more and better-quality clinical trial data in paediatric medicine, a strategic plan was developed and a new EU Paediatric Regulation came into force in 2007 (Regulations EC nos. 1901/2006 and 1902/2006, available at http://www.ema.europa.eu/). On the one hand, pharmaceutical companies were legally obliged to perform studies in paediatric patients if they intended to develop medicines for use in the adult population, and to prepare a paediatric drug development plan, the
Limited public acceptance of treating children with medications
Until not too long ago, in many European countries the treatment for child and adolescent psychiatric disorders was largely confined to behavioural and psychosocial interventions. The use of psychotropic medications remained a relative rarity through the 1990s. Afterwards, a rapid increase in prescription rates has occurred, especially for methylphenidate (Dalsgaard et al., 2013) and, to a lesser extent, for SGAs (Steinhausen, 2015, Olfson et al., 2012). Reservations around medication treatment
European collaborative efforts and future directions
The issues and problems presented in each section of this article need specific solutions, which require a solid and overarching logistic infrastructure at the European level and beyond, fostering intense collaboration among clinicians and scientists with diverse cultural approaches, clinical background and pre-clinical expertise. This infrastructure can then in turn implement innovative strategies to generate and analyze large biological databases, and to translate innovation into clinical
Role of the funding source
None of the agencies which funded the authors had any role in the writing of this report and in the decision to submit the paper for publication.
Contributors
Antonio M. Persico took notes during the TNM meeting, outlined the paper’s content, contributed to writing the paper’s versions and collated sections provided by co-authors. Celso Arango and Jan K. Buitelaar chaired the TNM meeting and contributed to the writing of the paper. Christoph U. Correll, Benedetto Vitiello, Carmen Moreno, Alessandro Zuddas, Pieter J. Hoekstra, Jacob Vorstman, and Jeffrey C. Glennon were either presenters or discussants at the TNM meeting, shared notes and slides, and
Conflict of interest statement
AMP, BV and JV have no conflict of interest to declare. CA has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Takeda and Schering Plough. JKB has been in the past 3
Acknowledgments
The authors would like to acknowledge the other participants to the TNM meeting for helpful discussion. This work has been supported by the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement numbers 242959 (PERS), 278948 (TACTICS), 260576 (ADDUCE), 261411 (STOP), 603016 (MATRICS), and 602805 (AGGRESSOTYPE), 241909 (EU-GEI), 242114 (OPTiMISE), 603196 (PSYSCAN) and 602478 (METSY), and the Innovative Medicines Initiative Joint Undertaking under grant agreement
References (152)
Present and future of developmental neuropsychopharmacology
Eur. Neuropsychopharmacol.
(2015)- et al.
The mGluR theory of fragile X mental retardation
Trends Neurosci.
(2004) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes
J. Am. Acad. Child Adolesc. Psychiatry
(2008)- et al.
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
Neurobiol. Dis.
(2008) - et al.
Correction of fragile X syndrome in mice
Neuron
(2007) - et al.
A double-blind pilot study of risperidone in the treatment of conduct disorder
J. Am. Acad. Child Adolesc. Psychiatry
(2000) - et al.
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons
Eur. Neuropsychopharmacol.
(2011) - et al.
Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study
Schizophr. Res.
(2012) - et al.
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
Lancet Oncol.
(2014) - et al.
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox
Cell
(1991)
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder
J. Am. Acad. Child Adolesc. Psychiatry
Schizophrenia as a disorder of molecular pathways
Biol. Psychiatry
Molecular genetics of neuronal migration disorders
Curr. Neurol. Neurosci. Rep.
AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology
J. Am. Acad. Child Adolesc. Psychiatry
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
J. Am. Acad. Child Adolesc. Psychiatry
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study
J. Am. Acad. Child Adolesc. Psychiatry
Neural mechanisms of attention-deficit/hyperactivity disorder symptoms are stratified by MAOA genotype
Biol. Psychiatry
Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
Transl. Psychiatry
Progressive brain changes in children and adolescents with first-episode psychosis
Arch. Gen. Psychiatry
Second-generation antipsychotics in children and adolescents: a six-month prospective cohort study in drug-naive patients
J. Am. Acad. Child Adolesc. Psychiatry
Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders
Schizophr. Bull.
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis
J. Clin. Psychiatry
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder
J. Child Adolesc. Psychopharmacol.
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update
Drug Saf.
Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study
J. Dev. Behav. Pediatr.
Young adult follow-up of hyperactive children: antisocial activities and drug use
J. Child Psychol. Psychiatry
Diagnostic inflation: causes and a suggested cure
J. Nerv. Ment. Dis.
Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder
PLoS Genet.
Modeling psychiatric disorders at the cellular and network levels
Mol. Psychiatry
Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials
JAMA
Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder
Am. J. Psychiatry
Behavioral signatures related to genetic disorders in autism
Mol. Autism
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
Neuropsychiatr. Dis. Treat.
Autism spectrum phenotype in males and females with fragile X full mutation and premutation
J. Autism Dev. Disord.
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders
Psychopharmacology (Berl.)
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children
BMJ
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
JAMA
Research in people with psychosis risk syndrome: a review of the current evidence and future directions
J. Child Psychol. Psychiatry
Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics
J. Clin. Psychiatry
Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults?
J. Child Psychol. Psychiatry
Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial
JAMA
Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study
J. Child Adolesc. Psychopharmacol.
Synaptic, transcriptional and chromatin genes disrupted in autism
Nature
iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth
Stem Cells Dev.
Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study
Eur. Child Adolesc. Psychiatry
The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals
Hum. Mol. Genet.
Pharmacovigilance in child and adolescent psychiatry
Z. Kinder Jugendpsychiatr. Psychother.
Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder
Nat. Genet.
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder
J. Child Adolesc. Psychopharmacol.
Cited by (59)
Psychopharmacology in children and adolescents: unmet needs and opportunities
2024, The Lancet PsychiatryThe pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present
2021, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :These two systematic contributions, organized “by drug”, shall be followed by a third and conclusive article, aimed to provide an overview of available pharmacological options “by symptom”. The overarching aim of our effort is to help clinicians personalize the pharmacological therapies of their autistic patients, basing their prescription as much as possible on currently available scientific evidence, also considering that the vast majority of prescriptions of psychoactive drugs in child and adolescent neuropsychiatry occurs off-label (Persico et al., 2015; Sharma et al., 2016). The tremendous interindividual differences in ASD pathogenesis, clinical presentation and treatment response clearly imply that only evidence-based and individually tailored pharmacological therapies hold a real promise to improve the quality of life of autistic patients and of their family members.
Autisms
2020, Neurodevelopmental Disorders: Comprehensive Developmental NeuroscienceIncidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE)
2019, European NeuropsychopharmacologyCitation Excerpt :For example, among children, metabolic monitoring is carried out about two times less frequently than in the adult population (Morrato et al., 2010). The medium and long-term consequences of many AEs are poorly known for the pediatric population and non-industry funded pharmacovigilance studies on the long term effects of SGA are lacking (Persico et al., 2015). Many countries have developed specific guidelines for the follow-up of AP treatments in children and adolescents (e.g. USA, Canada, United Kingdom and Spain, Raffin et al., 2014; Kendall et al., 2013; Ho et al., 2011), including clinical, physical and biological parameters.